GLP-1 Agonists for Obesity—ReplyGLP-1 Agonists for Obesity—Reply
In Reply Dr Kurian and colleagues raise the option of surgical obesity treatments. These can be effective and cost-effective for individuals with appropriate indications. Yet many eligible patients opt for pharmacologic over surgical options. GLP-1 agonists also have far broader (and still expanding) indications, with at least 4-fold more US residents eligible. Identifying practical, effective, Read More
GLP-1 Agonists for ObesityGLP-1 Agonists for Obesity
To the Editor Dr Mozaffarian’s Viewpoint proposing a new solution to the cost and access issues plaguing GLP-1 agonists for weight loss contains serious misconceptions. To the Editor Dr Mozaffarian’s Viewpoint proposing a new solution to the cost and access issues plaguing GLP-1 agonists for weight loss contains serious misconceptions.
EHR Data Suggest Tirzepatide Outdoes Semaglutide for Weight LossEHR Data Suggest Tirzepatide Outdoes Semaglutide for Weight Loss
People with overweight or obesity who used tirzepatide lost about 7% more weight during the year after beginning treatment compared with those who used semaglutide, a recent observational study published in JAMA Internal Medicine found. However, the majority of people in both groups had lost 5% or more of their original body weight within 1 Read More
More Data About Risks, Benefits Might Change Breast Cancer Screening ChoiceMore Data About Risks, Benefits Might Change Breast Cancer Screening Choice
In April 2024, the US Preventive Services Task Force (USPSTF) recommended that women aged 40 to 74 years with an average risk of breast cancer undergo mammography screening every 2 years. This updated the USPSTF’s prior suggestion that women aged 40 to 49 years engage in shared decision-making with their clinician before deciding whether to be screened.
Clinical trial in Ireland challenges beliefs about Ozempic and similar new obesity treatmentsClinical trial in Ireland challenges beliefs about Ozempic and similar new obesity treatments
A study carried out in St Vincent’s University Hospital (SVUH) Dublin challenges the belief that weight-loss medications such as Ozempic, Wegovy or Monjaro work just by promoting satiety and making you eat less. A study carried out in St Vincent’s University Hospital (SVUH) Dublin challenges the belief that weight-loss medications such as Ozempic, Wegovy or Read More
Semaglutide-linked suicidal ideation identified in disproportionality analysisSemaglutide-linked suicidal ideation identified in disproportionality analysis
Semaglutide-associated suicidal ideation has been identified in a disproportionality analysis, according to a study published online Aug. 20 in JAMA Network Open. Semaglutide-associated suicidal ideation has been identified in a disproportionality analysis, according to a study published online Aug. 20 in JAMA Network Open.
Semaglutide Has Disproportionate Suicidality Signal, Analysis FindsSemaglutide Has Disproportionate Suicidality Signal, Analysis Finds
(MedPage Today) — A disproportionality analysis based on reports in a World Health Organization (WHO) database suggested a suicidal ideation signal with the GLP-1 receptor agonist semaglutide (Ozempic, Rybelsus, Wegovy). Between 2000 and 2023… (MedPage Today) — A disproportionality analysis based on reports in a World Health Organization (WHO) database suggested a suicidal ideation Read More
Zepbound Can Prevent Diabetes; Menopause and Cognition; Tandem’s Insulin Pump UpdateZepbound Can Prevent Diabetes; Menopause and Cognition; Tandem’s Insulin Pump Update
(MedPage Today) — In a phase III study of adults with pre-diabetes and obesity or overweight, tirzepatide (Zepbound) reduced the risk of developing type 2 diabetes by 94% over a 3-year period, Eli Lilly announced. In related news, real-world… (MedPage Today) — In a phase III study of adults with pre-diabetes and obesity or Read More
Mounjaro, Zepbound cut odds for diabetes by 94% in at-risk people, study findsMounjaro, Zepbound cut odds for diabetes by 94% in at-risk people, study finds
Tirzepatide, the blockbuster GLP-1 medicine known as Mounjaro for diabetes and Zepbound for weight loss, cut the odds that an obese, prediabetic person will develop diabetes by 94%, a new trial shows. Tirzepatide, the blockbuster GLP-1 medicine known as Mounjaro for diabetes and Zepbound for weight loss, cut the odds that an obese, prediabetic person Read More
Disproportionality Analysis From WHO Data on Semaglutide, Liraglutide, and SuicidalityDisproportionality Analysis From WHO Data on Semaglutide, Liraglutide, and Suicidality
This case control study evaluates potential signals for suicidal and self-injurious adverse drug reactions associated with semaglutide and liraglutide. This case control study evaluates potential signals for suicidal and self-injurious adverse drug reactions associated with semaglutide and liraglutide.